- Home
- QLGN vs PSTV Comparison
QLGN vs PSTV Comparison
Compare QLGN & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QLGN
- PSTV
- Stock Information
- Founded
- QLGN 1996
- PSTV 1996
- Country
- QLGN United States
- PSTV United States
- Employees
- QLGN N/A
- PSTV N/A
- Industry
- QLGN Biotechnology: Pharmaceutical Preparations
- PSTV Medical/Dental Instruments
- Sector
- QLGN Health Care
- PSTV Health Care
- Exchange
- QLGN Nasdaq
- PSTV Nasdaq
- Market Cap
- QLGN 2.2M
- PSTV 2.1M
- IPO Year
- QLGN N/A
- PSTV N/A
- Fundamental
- Price
- QLGN $3.48
- PSTV $0.79
- Analyst Decision
- QLGN
- PSTV Strong Buy
- Analyst Count
- QLGN 0
- PSTV 3
- Target Price
- QLGN N/A
- PSTV $11.50
- AVG Volume (30 Days)
- QLGN 158.4K
- PSTV 3.8M
- Earning Date
- QLGN 05-06-2025
- PSTV 05-14-2025
- Dividend Yield
- QLGN N/A
- PSTV N/A
- EPS Growth
- QLGN N/A
- PSTV N/A
- EPS
- QLGN N/A
- PSTV N/A
- Revenue
- QLGN N/A
- PSTV $5,824,000.00
- Revenue This Year
- QLGN N/A
- PSTV $13.26
- Revenue Next Year
- QLGN N/A
- PSTV $24.59
- P/E Ratio
- QLGN N/A
- PSTV N/A
- Revenue Growth
- QLGN N/A
- PSTV 18.54
- 52 Week Low
- QLGN $2.85
- PSTV $0.24
- 52 Week High
- QLGN $29.45
- PSTV $2.67
- Technical
- Relative Strength Index (RSI)
- QLGN 52.85
- PSTV 47.37
- Support Level
- QLGN $3.10
- PSTV $0.61
- Resistance Level
- QLGN $4.40
- PSTV $1.22
- Average True Range (ATR)
- QLGN 0.40
- PSTV 0.13
- MACD
- QLGN 0.05
- PSTV 0.02
- Stochastic Oscillator
- QLGN 40.32
- PSTV 29.16
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).